Back to Search
Start Over
Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
- Source :
- Blood, 141(21), 2657-2661. American Society of Hematology, Ngai, L L, Hanekamp, D, Janssen, F, Carbaat-Ham, J, Hofland, M A M A, Fayed, M M H E, Kelder, A, Oudshoorn-van Marsbergen, L, Scholten, W J, Snel, A N, Bachas, C, Tettero, J M, Breems, D A, Fischer, T, Gjertsen, B T, Griškevičius, L, Juliusson, G, van de Loosdrecht, A A, Maertens, J A, Manz, M G, Pabst, T, Passweg, J R, Porkka, K, Valk, P J M, Gradowska, P, Löwenberg, B, de Leeuw, D C, Janssen, J J W M, Ossenkoppele, G J & Cloos, J 2023, ' Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial ', Blood, vol. 141, no. 21, pp. 2657-2661 . https://doi.org/10.1182/blood.2022019160, https://doi.org/10.1182/blood.2022019160, Blood, 141, 21, pp. 2657-2661, Blood, 141, 2657-2661, Blood, Washington : Elsevier B.V., 2023, Early Access, p. [1-13]
- Publication Year :
- 2023
- Publisher :
- American Society of Hematology, 2023.
-
Abstract
- Item does not contain fulltext
Details
- Language :
- English
- ISSN :
- 15280020 and 00064971
- Volume :
- 141
- Issue :
- 21
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....080e814dcf13200d1ff53e8c4ead81a3